Oncology Brothers: Practice-Changing Cancer Discussions
Oncology Brothers
The Oncology Brothers Podcast, led by Drs. Rahul and Rohit Gosain, is dedicated to bridging the gap between academic cancer centers and community oncology in the ever-evolving field of hematology & oncology. With a mission to disseminate crucial information to the medical community, this oncology podcast is not for medical advice but rather serves as a beacon for physicians, nurses, trainees, and advanced practice providers (APPs) involved in the care of cancer patients.
Drs. Rahul and Rohit Gosain, both esteemed oncologists, bring a wealth of experience and expertise from their general community practice to these discussions. Through short and engaging interviews with world-renowned researchers, clinicians, hematologists, and oncologists, they present practice-changing data in a concise, bite-sized format.
Get the latest FDA approvals news, oncology conference highlights, and treatment algorithms in 25 minutes or less. Conversations center around common cancers you see in your clinic like breast cancer, prostate cancer, kidney cancer, bladder cancer, lung cancer, and GI cancers. With new indications and approvals, we talk about how to incorporate this data in your day to day clinical practice.
Each episode includes visual presentations so you can follow along within the podcast players and on YouTube @oncbrothers. These visual tools and algorithms will provide an outline on what is covered in each episode. Immediately apply the latest insights and advancements in your daily practice, ensuring the delivery of optimal cancer care to patients within your local communities.
If you want to navigate the complexities of your hematology & oncology practice and stay current, the Oncology Brothers Podcast offers invaluable insights and practical takeaways to enhance your professional journey and improve patient outcomes. For more information, please visit: www.oncbrothers.com, and connect with us on Twitter/X/Instagram/TikTok: @oncbrothers, or email us at info@oncbrothers.com
Drs. Rahul and Rohit Gosain, both esteemed oncologists, bring a wealth of experience and expertise from their general community practice to these discussions. Through short and engaging interviews with world-renowned researchers, clinicians, hematologists, and oncologists, they present practice-changing data in a concise, bite-sized format.
Get the latest FDA approvals news, oncology conference highlights, and treatment algorithms in 25 minutes or less. Conversations center around common cancers you see in your clinic like breast cancer, prostate cancer, kidney cancer, bladder cancer, lung cancer, and GI cancers. With new indications and approvals, we talk about how to incorporate this data in your day to day clinical practice.
Each episode includes visual presentations so you can follow along within the podcast players and on YouTube @oncbrothers. These visual tools and algorithms will provide an outline on what is covered in each episode. Immediately apply the latest insights and advancements in your daily practice, ensuring the delivery of optimal cancer care to patients within your local communities.
If you want to navigate the complexities of your hematology & oncology practice and stay current, the Oncology Brothers Podcast offers invaluable insights and practical takeaways to enhance your professional journey and improve patient outcomes. For more information, please visit: www.oncbrothers.com, and connect with us on Twitter/X/Instagram/TikTok: @oncbrothers, or email us at info@oncbrothers.com
Episodes
Mentioned books
Mar 24, 2025 • 27min
Prostate Cancer Management from Early Stage to Advanced Metastatic Disease - Dr. Alan Bryce
Join us in this insightful episode of the Oncology Brothers podcast as we dive deep into the current treatment landscape of prostate cancer with Dr. Alan Bryce, Chief Clinical Officer and GU Medical Oncologist from City of Hope.
In this episode, we explore:
• The treatment paradigm for early-stage prostate cancer, including the role of active surveillance and the use of abiraterone based on the STAMPEDE trial.
• The importance of understanding risk factors and treatment options for low, intermediate, and high-risk patients.
• The implications of PET-PSMA imaging versus conventional CT modalities in staging and treatment decisions.
• The management of biochemical recurrent disease and the significance of PSA doubling time in treatment planning.
• The role of PARP inhibitors in patients with HRR mutations and the nuances of selecting appropriate therapies.
• Strategies for managing metastatic disease, including the use of Lutetium-177 (Pluvicto) and cabazitaxel.
Dr. Bryce provides a masterclass on navigating the complexities of prostate cancer treatment, emphasizing the need to balance between over-treatment in early disease and under-treatment in metastatic cases.
YouTube: https://youtu.be/Zfu-yGmH0rg
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
If you find this episode helpful, please share it with your colleagues and leave us a review! Don't forget to check out our other episodes in the GU treatment algorithm series, including discussions on renal cell carcinoma and bladder cancer.
Mar 17, 2025 • 20min
How to Treat Renal Cell Carcinoma (RCC) using a Treatment Algorithm with Dr. Katy Beckermann
Join us for an insightful episode of the Oncology Brothers podcast as we dive deep into the world of renal cell carcinoma (RCC) with Dr. Katy Beckermann, the Medical GU Director of Cancer Research at Tennessee Oncology.
In this episode, hosts Drs. Rahul & Rohit Gosain, practicing medical oncologists, discuss the latest advancements in RCC treatment, including:
• The role of Pembrolizumab in the adjuvant setting based on the Keynote 564 study and its implications for early-stage disease.
• Current treatment paradigms for metastatic RCC, including dual checkpoint inhibitors, TKI with immunotherapy, and single-agent options.
• The importance of patient characteristics and IMDC risk categorization in treatment decisions.
• Insights into sequencing therapies, including the use of Belzutifan for refractory disease and the management of side effects.
• The role of ctDNA, PD-L1 testing, and NGS in RCC.
Whether you're a community oncologist or simply interested in the latest in cancer care, this episode is packed with valuable information to help you stay informed and provide the best care for your patients.
YouTube: https://youtu.be/Bbv9N7-YKIM
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and leave a review to let us know how we're doing and how we can continue to support you in the community!
Mar 10, 2025 • 22min
How to Treat Bladder Cancer in 2025 with Dr. Joaquim Bellmunt
Join Drs. Rahul & Rohit Gosain in this insightful episode of the Oncology Brothers podcast as they continue their treatment algorithm series, focusing on the rapidly evolving landscape of bladder cancer. They are joined by Dr. Joaquim Bellmunt, a medical oncologist and director of bladder cancer at the Dana-Farber Cancer Institute, who shares his expertise on the latest treatment paradigms for both muscle invasive and non-muscle invasive bladder cancer.
In this episode, you'll learn about:
• The distinction between muscle invasive and non-muscle invasive bladder cancer and their respective treatment approaches.
• The role of BCG treatment and emerging options for BCG-refractory disease.
• The significance of the NIAGARA trial and its implications for neoadjuvant chemotherapy and perioperative immunotherapy.
• Current strategies for managing muscle invasive bladder cancer, including the use of cisplatin-based therapies and the introduction of immunotherapy.
• Insights into the metastatic space, including the use of enfortumab vedotin (EV) and pembrolizumab, and the importance of next-generation sequencing (NGS) in treatment decisions.
• Key side effects to monitor with various treatments and the importance of maintaining quality of life for patients.
Whether you're a healthcare professional or simply interested in the latest advancements in oncology, this episode is packed with valuable information.
YouTube: https://youtu.be/apUp2-BkgWQ
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to like, share, and subscribe for more discussions on cancer treatment algorithms!
Mar 6, 2025 • 20min
FDA Approval of Tislelizumab - RATIONALE 305 and 306 in Upper GI Cancers
Welcome to the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by Dr. Anwaar Saeed, Chief of GI Medical Oncology at UPMC, to discuss the recent approval of Tislelizumab, a new checkpoint inhibitor for upper GI malignancies, including esophageal squamous cell cancer, GE junction, and gastric cancer.
We dive deep into the studies that led to Tislelizumab’s approval, including the Rationale 302, 305, and 306 trials. Dr. Saeed explains the unique mechanism of action of Tislelizumab, its higher binding affinity to PD-1, and how it compares to other PD-1 inhibitors like nivolumab and pembrolizumab.
Key topics covered in this episode:
• Overview of Tislelizumab and its mechanism of action
• Insights from the Rationale 306 trial and its implications for frontline treatment
• Discussion on the Rationale 305 trial focusing on adenocarcinoma
• The importance of PD-L1 testing and biomarker-driven treatment decisions
• Side effect profiles of Tislelizumab compared to other immunotherapies
• Future directions in the use of immunotherapy for upper GI malignancies
Join us for this informative discussion that highlights the evolving landscape of cancer treatment and the importance of precision oncology. If you find this episode helpful, please share it with your colleagues and leave us a review!
YouTube: https://youtu.be/hQeLdpSzGCk
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to subscribe for more practice-changing discussions in the world of oncology. We are the Oncology Brothers!
Mar 3, 2025 • 22min
GU ASCO 2025 Highlights - TALAPRO-2, NIAGARA, CheckMate-9ER, TiNivo-2
Welcome to another episode of the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by Dr. Toni Choueiri, a leading GU medical oncologist from Dana-Farber Cancer Institute. Together, they dive into the highlights from the GU ASCO 2025 conference, covering key studies and updates in the world of genitourinary oncology.
Episode Highlights:
• TALAPRO-2: An in-depth discussion on the role of PARP inhibitors in prostate cancer, focusing on the study's design, findings, and the importance of germline and NGS testing.
• NIAGARA Update: Insights into the new standard of care for resectable muscle-invasive bladder cancer and the promising results from the perioperative approach with Durvalumab.
• CheckMate-9ER Update: A look at the combination of Cabozantinib and Nivolumab in first-line metastatic RCC, including the latest findings and implications for treatment beyond the first line.
• TiNivo2: Exploring the role of Tivozanib in the treatment landscape of RCC and potential sequencing strategies.
Join us for this informative discussion that aims to keep community oncologists up to date with the latest advancements in cancer care. If you find this episode helpful, please share it with your colleagues and leave us a review!
YouTube: https://youtu.be/OzeHhyAdF9Q
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to subscribe for more insights and updates from the Oncology Brothers!
Feb 24, 2025 • 21min
How to Treat Hormone Receptor Positive Cancer - Latest Advancements and Current Standard of Care in 2025
In this enlightening discussion, Dr. Kevin Kalinsky, a leading breast medical oncologist and director of the breast cancer program at Emory University's Winship Cancer Institute, shares groundbreaking insights into the treatment of hormone receptor-positive breast cancer. He emphasizes the role of OncotypeDX in determining chemotherapy for different menopausal statuses and delves into the promising implications of new therapies like Inavolisib and CDK4-6 inhibitors. The conversation also explores genomic assays and ongoing trials that may reshape future treatment protocols.
Feb 21, 2025 • 23min
FDA Approval of Zolbetuximab SPOTLIGHT / GLOW study - Upper GI Cancer with Claudin 18.2 Mutation
In this episode of the Oncology Brothers podcast, Drs. Rahul and Rohit Gosain dive into the recent advancements in the treatment of gastroesophageal junction (GEJ) and gastric cancer, focusing on the newly approved drug Zolbetuximab. They are joined by Dr. Kohei Shitara, the lead author of the pivotal SPOTLIGHT study, who shared insights on the mechanism of action of Zolbetuximab, its clinical trial findings, and the implications for patient care.
Key topics discussed include:
• The mechanism of action of Zolbetuximab and its target, Claudin 18.2.
• An overview of the GLOW and SPOTLIGHT studies, including study design and key findings on progression-free survival (PFS) and overall survival (OS).
• Practical considerations for administering Zolbetuximab in clinical practice, including dosing schedules and side effect management.
• The importance of testing for Claudin 18.2 and the challenges faced in rural settings without in-house testing.
• Future directions in the treatment landscape for gastric cancer, including potential combination therapies and emerging agents.
Join us for this informative discussion that highlights the changing standard of care in gastric cancer treatment and the exciting possibilities ahead for patients.
Don't forget to like, share, and subscribe for more insightful conversations in the world of oncology!
YouTube: https://youtu.be/BfpDHpqgHMs
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
Feb 17, 2025 • 23min
How to Treat HER2+ Breast Cancer - Discussion with Dr. Sarah Sammons
Join Dr. Sarah Sammons, a medical oncologist at Dana-Farber Cancer Institute, as she discusses groundbreaking insights into HER2-positive breast cancer treatment. She explores treatment options for early-stage HER2-positive patients, including key findings from the APT trial. The conversation shifts to the latest data from the PATINA trial, revealing its implications for metastatic cases. Dr. Sammons also highlights innovations like T-DXd for brain metastases and the management of toxicities with neoadjuvant therapies. Tune in for practical pearls that could transform treatment decisions!
Feb 10, 2025 • 17min
How to Treat Triple Negative Breast Cancer - Discussion with Dr. Virginia Kaklamani
Welcome to the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Virginia Kaklamani from the UTHealth San Antonio MD Anderson Cancer Center to discuss the latest advances in the treatment of triple negative breast cancer (TNBC) as we kick off 2025.
• The treatment paradigms for early-stage TNBC, including the role Sacituzumab and radiation therapy.
• Insights from the SABCS 2024 conference, focusing on the keynote 522 regimen and its implications for neoadjuvant treatment.
• The management of locally advanced and metastatic TNBC, including the use of immunotherapy and the importance of PD-L1 testing.
• Strategies for managing toxicities associated with treatments like sacituzumab and T-DXd.
Whether you're a healthcare professional or someone interested in the latest in oncology, this episode provides valuable insights into the evolving landscape of breast cancer treatment. Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!
Key Takeaways:
• Current standard of care for locally advanced TNBC.
• The significance of chemotherapy and immunotherapy in treatment plans.
• Managing toxicities in metastatic disease.
Stay tuned for more discussions on treatment algorithms, FDA approvals, and clinical pearls in oncology!
YouTube: https://youtu.be/GfROoYPVb_8
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
Feb 3, 2025 • 21min
GI ASCO 2025 Highlights - BREAKWATER, CheckMate-8HW, ALASCCA, STARTER-NET
Welcome to another episode of the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by Dr. Alok Khorana, a GI medical oncologist from the Cleveland Clinic, to discuss the latest highlights from the GI ASCO 2025 conference.
We dive into four key studies that are practice-informing and potentially practice-changing:
1. BREAKWATER: We explore the implications of using Encorafenib and Cetuximab in combination with FOLFOX for patients with BRAF V600E mutations, which are associated with poor prognosis.
2. CheckMate-8HW: This study investigates whether dual checkpoint inhibition is more effective than single-agent immunotherapy for MSI-high patients, revealing promising results in progression-free survival.
3. Aspirin in Adjuvant Settings: We discuss the role of low-dose aspirin in reducing recurrence rates for patients with PI3K alterations, highlighting its potential as a practice-changing intervention.
4. STARTER-NET: Finally, we review the findings from the study on Everolimus combined with Lanreotide for neuroendocrine tumors, noting the lack of overall survival benefit.
Tune in for an insightful discussion on these important topics in oncology, and learn how these findings could impact treatment strategies in your practice. Don't forget to like, subscribe, and check out our other episodes for more conference highlights and treatment discussions!
YouTube: https://youtu.be/YOToz3hKYTg
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
#OncologyBrothers #GIASCO2025 #ColorectalCancer #Immunotherapy #NeuroendocrineTumors #CancerResearch #Podcast
